Cystic Fibrosis Transmembrane Conductance Regulator

"Cystic Fibrosis Transmembrane Conductance Regulator" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A chloride channel that regulates secretion in many exocrine tissues. Abnormalities in the CFTR gene have been shown to cause cystic fibrosis. (Hum Genet 1994;93(4):364-8)

Descriptor ID	D019005
MeSH Number(s)	D12.776.157.530.100.304.500 D12.776.157.530.400.175.125 D12.776.157.530.450.074.500.500.500.500 D12.776.543.550.450.175.125 D12.776.543.585.100.304.500 D12.776.543.585.400.175.125 D12.776.543.585.450.074.500.500.500.500
Concept/Terms	Cystic Fibrosis Transmembrane Conductance Regulator Cystic Fibrosis Transmembrane Conductance Regulator CFTR Protein Protein, CFTR Chloride channels, ATP-gated CFTR Chloride channels, ATP gated CFTR

Below are MeSH descriptors whose meaning is more general than "Cystic Fibrosis Transmembrane Conductance Regulator".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Carrier Proteins [D12.776.157]
Membrane Transport Proteins [D12.776.157.530]
ATP-Binding Cassette Transporters [D12.776.157.530.100]
Multidrug Resistance-Associated Proteins [D12.776.157.530.100.304]
Cystic Fibrosis Transmembrane Conductance Regulator [D12.776.157.530.100.304.500]
Ion Channels [D12.776.157.530.400]
Chloride Channels [D12.776.157.530.400.175]
Cystic Fibrosis Transmembrane Conductance Regulator [D12.776.157.530.400.175.125]
Ion Pumps [D12.776.157.530.450]
Anion Transport Proteins [D12.776.157.530.450.074]
Organic Anion Transporters [D12.776.157.530.450.074.500]
Organic Anion Transporters, ATP-Dependent [D12.776.157.530.450.074.500.500]
Multidrug Resistance-Associated Proteins [D12.776.157.530.450.074.500.500.500]
Cystic Fibrosis Transmembrane Conductance Regulator [D12.776.157.530.450.074.500.500.500.500]
Membrane Proteins [D12.776.543]
Membrane Glycoproteins [D12.776.543.550]
Ion Channels [D12.776.543.550.450]
Chloride Channels [D12.776.543.550.450.175]
Cystic Fibrosis Transmembrane Conductance Regulator [D12.776.543.550.450.175.125]
Membrane Transport Proteins [D12.776.543.585]
ATP-Binding Cassette Transporters [D12.776.543.585.100]
Multidrug Resistance-Associated Proteins [D12.776.543.585.100.304]
Cystic Fibrosis Transmembrane Conductance Regulator [D12.776.543.585.100.304.500]
Ion Channels [D12.776.543.585.400]
Chloride Channels [D12.776.543.585.400.175]
Cystic Fibrosis Transmembrane Conductance Regulator [D12.776.543.585.400.175.125]
Ion Pumps [D12.776.543.585.450]
Anion Transport Proteins [D12.776.543.585.450.074]
Organic Anion Transporters [D12.776.543.585.450.074.500]
Organic Anion Transporters, ATP-Dependent [D12.776.543.585.450.074.500.500]
Multidrug Resistance-Associated Proteins [D12.776.543.585.450.074.500.500.500]
Cystic Fibrosis Transmembrane Conductance Regulator [D12.776.543.585.450.074.500.500.500.500]

Below are MeSH descriptors whose meaning is related to "Cystic Fibrosis Transmembrane Conductance Regulator".

Below are MeSH descriptors whose meaning is more specific than "Cystic Fibrosis Transmembrane Conductance Regulator".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cystic Fibrosis Transmembrane Conductance Regulator" by people in this website by year, and whether "Cystic Fibrosis Transmembrane Conductance Regulator" was a major or minor topic of these publications.

Bar chart showing 38 publications over 22 distinct years, with a maximum of 4 publications in 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1993	0	1	1
1995	0	1	1
2001	1	1	2
2004	2	0	2
2005	0	2	2
2006	1	0	1
2007	1	1	2
2008	0	2	2
2009	1	1	2
2010	1	0	1
2011	1	0	1
2012	1	0	1
2013	0	1	1
2014	1	0	1
2015	1	1	2
2016	3	0	3
2017	2	0	2
2018	0	2	2
2019	2	2	4
2020	1	1	2
2021	1	0	1
2022	0	2	2

Below are the most recent publications written about "Cystic Fibrosis Transmembrane Conductance Regulator" by people in Profiles.

Szentpetery S, Foil K, Hendrix S, Gray S, Mingora C, Head B, Johnson D, Flume PA. A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus. J Cyst Fibros. 2022 07; 21(4):721-724.

View in: PubMed
Spielman DB, Beswick DM, Kimple AJ, Senior BA, Aanaes K, Woodworth BA, Schlosser RJ, Lee S, Cho DY, Adappa ND, DiMango E, Gudis DA. The management of cystic fibrosis chronic rhinosinusitis: An evidenced-based review with recommendations. Int Forum Allergy Rhinol. 2022 Sep; 12(9):1148-1183.

View in: PubMed
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respir Med. 2021 07; 9(7):733-746.

View in: PubMed
Ng C, Nadig T, Smyth AR, Flume P. Treatment of pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 2020 11; 26(6):679-684.

View in: PubMed
Mayer-Hamblett N, van Koningsbruggen-Rietschel S, Nichols DP, VanDevanter DR, Davies JC, Lee T, Durmowicz AG, Ratjen F, Konstan MW, Pearson K, Bell SC, Clancy JP, Taylor-Cousar JL, De Boeck K, Donaldson SH, Downey DG, Flume PA, Drevinek P, Goss CH, Fajac I, Magaret AS, Quon BS, Singleton SM, VanDalfsen JM, Retsch-Bogart GZ. Building global development strategies for cf therapeutics during a transitional cftr modulator era. J Cyst Fibros. 2020 09; 19(5):677-687.

View in: PubMed
Walker S, Flume P, McNamara J, Solomon M, Chilvers M, Chmiel J, Harris RS, Haseltine E, Stiles D, Li C, Ahluwalia N, Zhou H, Owen CA, Sawicki G. A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11?years with cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):708-713.

View in: PubMed
Brothers KB, Devereaux M, Sade RM. Bespoke Babies: Genome Editing in Cystic Fibrosis Embryos. Ann Thorac Surg. 2019 10; 108(4):995-999.

View in: PubMed
Fernandez-Petty CM, Hughes GW, Bowers HL, Watson JD, Rosen BH, Townsend SM, Santos C, Ridley CE, Chu KK, Birket SE, Li Y, Leung HM, Mazur M, Garcia BA, Evans TIA, Libby EF, Hathorne H, Hanes J, Tearney GJ, Clancy JP, Engelhardt JF, Swords WE, Thornton DJ, Wiesmann WP, Baker SM, Rowe SM. A glycopolymer improves vascoelasticity and mucociliary transport of abnormal cystic fibrosis mucus. JCI Insight. 2019 04 18; 4(8).

View in: PubMed
Flume PA. The study of CFTR modulators in the very young. Lancet Respir Med. 2019 04; 7(4):287-289.

View in: PubMed
Jennings MT, Flume PA. Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies. Ann Am Thorac Soc. 2018 08; 15(8):897-902.

View in: PubMed

People

Explore

Similar Concepts

Top Journals